Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kyverna Therapeutics
Biotech
Kyverna CEO: 'We're in the next phase of medicine'
Kyverna's public proceeds will help finance operations into 2026.
Max Bayer
Feb 9, 2024 1:57pm
Kyverna overshoots raised IPO expectations with $319M offering
Feb 8, 2024 8:24am
Kyverna raises IPO expectations to almost $300M
Feb 6, 2024 9:46am
Kyverna eyes $180M IPO haul to fund autoimmune CAR-T trials
Feb 1, 2024 9:45am
Kyverna accelerates into another FDA fast track
Jan 19, 2024 10:26am
CAR-T developer Kyverna is latest clue biotech IPOs are back
Jan 17, 2024 7:22am